Name: UMIN ID:
Unique ID issued by UMIN | UMIN000018217 |
---|---|
Receipt number | R000021085 |
Scientific Title | A randomized phase II study to investigate the deepness of response of FOLFOXIRI plus cetuximab (Erbitux) versus FOLFOXIRI plus bevacizumab as the first-line therapy in metastatic colorectal cancer patients with RAS wild-type tumors: DEEPER |
Date of disclosure of the study information | 2015/07/15 |
Last modified on | 2020/07/21 10:22:38 |
No. | Disposal | Last modified on | Item of update | |
---|---|---|---|---|
1 | Insert | 2015/07/06 17:00:17 | ||
2 | Update | 2016/11/15 13:57:37 | Interventions/Control_1 Key inclusion criteria |
|
3 | Update | 2016/11/15 13:58:08 | Name of primary person or sponsor Organization Organization |
|
4 | Update | 2016/11/15 13:59:51 | Last follow-up date Date of closure to data entry Date trial data considered complete Date analysis concluded |
|
5 | Update | 2020/07/21 10:19:43 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Zip code Last name of contact person Last name of contact person Zip code Organization1 Organization Organization Address Address Tel Institutions |
|
6 | Update | 2020/07/21 10:22:12 | Recruitment status Date of IRB Last follow-up date Date of closure to data entry Date trial data considered complete Date analysis concluded |
|
7 | Update | 2020/07/21 10:22:38 | Number of participants that the trial has enrolled |